Summary
48.91 -0.37(-0.75%)07/01/2024
Twist Bioscience Corp (TWST)
Twist Bioscience Corp (TWST)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.75 | -3.49 | 16.10 | 42.95 | 28.92 | 155.03 | 69.41 | 251.04 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 48.91 | |
| Open | 48.29 | |
| High | 51.25 | |
| Low | 48.29 | |
| Volume | 892,629 | |
| Change | -0.37 | |
| Change % | -0.75 | |
| Avg Volume (20 Days) | 795,316 | |
| Volume/Avg Volume (20 Days) Ratio | 1.12 | |
| 52 Week Range | 14.43 - 55.19 | |
| Price vs 52 Week High | -11.38% | |
| Price vs 52 Week Low | 238.95% | |
| Range | 1.77 | |
| Gap Up/Down | 0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,869 | |
| EBIDTA | -91,035,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 116.83 | |
| Book Value | 11.7340 | |
| Earnings Per Share | -3.1520 | |
| EPS Estimate Current Quarter | -0.7900 | |
| EPS Estimate Next Quarter | -0.7500 | |
| EPS Estimate Current Year | -3.1500 | |
| EPS Estimate Next Year | -3.2100 | |
| Diluted EPS (TTM) | -3.1520 | |
| Revenues | ||
| Profit Marging | -1.1494 | |
| Operating Marging (TTM) | -1.1581 | |
| Return on asset (TTM) | -0.1740 | |
| Return on equity (TTM) | -0.3317 | |
| Revenue TTM | 132,333,000 | |
| Revenue per share TTM | 2.7430 | |
| Quarterly Revenue Growth (YOY) | 0.1700 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 51,713,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.1011 | |
| Revenue Enterprise Value | 28.0317 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 49,632,500 | |
| Shares Float | 47,367,753 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 7.41 | |
| Institutions (%) | 98.80 | |
06/06 08:00 EST - businesswire.com
Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy. The study titled, “Discovery of a potent, selective, and tumor-suppress.
Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication of a study detailing the discovery of TB206-001, a first-in-class antibody targeting adenosine A2A receptor (A2AR), a promising molecular target that could enhance cancer immunotherapy. The study titled, “Discovery of a potent, selective, and tumor-suppress.
06/04 08:00 EST - businesswire.com
Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the company has joined the U.S. AI Safety Institute Consortium (AISIC), a group established by the Department of Commerce's National Institute of Standards and Technology (NIST) to support the development and deployment of trustworthy and safe AI. “Biosecurity has bee.
Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the company has joined the U.S. AI Safety Institute Consortium (AISIC), a group established by the Department of Commerce's National Institute of Standards and Technology (NIST) to support the development and deployment of trustworthy and safe AI. “Biosecurity has bee.
05/23 08:00 EST - businesswire.com
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will present and participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, in.
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will present and participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, in.
05/22 13:01 EST - zacks.com
What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?
Does Twist Bioscience (TWST) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?
Does Twist Bioscience (TWST) have what it takes to be a top stock pick for momentum investors? Let's find out.
05/13 08:00 EST - businesswire.com
Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA (dsDNA) up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications. “Using our chemical synthesis platform we are.
Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-throughput Screening Applications
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments (MGFs), pools of directly synthesized double-stranded DNA (dsDNA) up to 500 base pairs in length with no limit on sequence number to enable high throughput screening applications. “Using our chemical synthesis platform we are.
05/10 06:00 EST - investorplace.com
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.
05/08 08:00 EST - businesswire.com
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist. The employment ind.
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist. The employment ind.
05/02 22:54 EST - seekingalpha.com
Twist Bioscience Corporation (TWST) Q2 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Steven Mah - Cowen Tom Peterson - Baird Operator Welcome to Twist Bioscience's Fiscal 2024 Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode.
Twist Bioscience Corporation (TWST) Q2 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Steven Mah - Cowen Tom Peterson - Baird Operator Welcome to Twist Bioscience's Fiscal 2024 Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode.
05/02 18:36 EST - zacks.com
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.06 per share a year ago.
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.06 per share a year ago.
04/30 15:20 EST - investorplace.com
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine.
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine.
04/18 08:00 EST - businesswire.com
Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss.
Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss.
03/28 08:00 EST - businesswire.com
Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing (WES). “No one single human genome can serve as a reference representing everyone. I.
Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome sequencing (WES). “No one single human genome can serve as a reference representing everyone. I.
03/05 08:00 EST - businesswire.com
Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced European Union (EU) in vitro diagnostic regulations (IVDR) compliant Twist Precision Dx next-generation sequencing (NGS) Products. In accordance with the IVD regulations put in place by the EU to ensure the safety and quality of in vitro diagnostic medical devices, Twist's.
Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced European Union (EU) in vitro diagnostic regulations (IVDR) compliant Twist Precision Dx next-generation sequencing (NGS) Products. In accordance with the IVD regulations put in place by the EU to ensure the safety and quality of in vitro diagnostic medical devices, Twist's.
02/13 13:59 EST - investorplace.com
7 Stocks Cathie Wood Is Still Loading Up On in Q1
You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.
7 Stocks Cathie Wood Is Still Loading Up On in Q1
You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.
02/11 15:44 EST - investorplace.com
7 Sexy Stocks That Will Continue to Outperform in 2024
While 2023 was the year of the Magnificent Seven, the seven outperforming stocks in this article are likely to be winners that will surge past the broader indices, such as the S&P 500 and the Nasdaq. The reason is that these companies trade at low valuations and have robust outlooks for this year and beyond.
7 Sexy Stocks That Will Continue to Outperform in 2024
While 2023 was the year of the Magnificent Seven, the seven outperforming stocks in this article are likely to be winners that will surge past the broader indices, such as the S&P 500 and the Nasdaq. The reason is that these companies trade at low valuations and have robust outlooks for this year and beyond.
02/07 09:22 EST - seekingalpha.com
Twist Bioscience: Strong Performance In A Soft Market
Twist Bioscience reported strong results in the first quarter of FY2024, despite a tepid demand environment. Growth was somewhat exaggerated by lumpy NGS revenue, but overall the business is progressing well, particularly from a profitability perspective. Twist's share price has increased significantly in recent months, which probably means that near-term upside is limited.
Twist Bioscience: Strong Performance In A Soft Market
Twist Bioscience reported strong results in the first quarter of FY2024, despite a tepid demand environment. Growth was somewhat exaggerated by lumpy NGS revenue, but overall the business is progressing well, particularly from a profitability perspective. Twist's share price has increased significantly in recent months, which probably means that near-term upside is limited.
02/07 08:00 EST - businesswire.com
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 122,400 restricted stock units (“RSUs”) to 36 recently hired individuals as an inducement material to their acceptance of employment with Twist. The employment in.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 122,400 restricted stock units (“RSUs”) to 36 recently hired individuals as an inducement material to their acceptance of employment with Twist. The employment in.
02/06 08:05 EST - businesswire.com
Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element's AVITI™ System. “Element continues to expand its customer.
Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System
SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element's AVITI™ System. “Element continues to expand its customer.
02/05 08:00 EST - businesswire.com
Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced technology early access of the Twist Flex Prep Ultra High-Throughput (UHT) Kit, which aims to enable unparalleled throughput at a fraction of the cost of existing on market solutions, accelerating NGS' microarray conversion and adoption in agricultural genomics. Built upon.
Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced technology early access of the Twist Flex Prep Ultra High-Throughput (UHT) Kit, which aims to enable unparalleled throughput at a fraction of the cost of existing on market solutions, accelerating NGS' microarray conversion and adoption in agricultural genomics. Built upon.
02/02 13:11 EST - seekingalpha.com
Twist Bioscience Corporation (TWST) Q1 2024 Earnings Call Transcript
Twist Bioscience Corporation (TWST) Q1 2024 Earnings Call Transcript
Twist Bioscience Corporation (TWST) Q1 2024 Earnings Call Transcript
Twist Bioscience Corporation (TWST) Q1 2024 Earnings Call Transcript